Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children with Primary Hyperoxaluria Type 1

Trial Profile

ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children with Primary Hyperoxaluria Type 1

Planning
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs Lumasiran (Primary)
  • Indications Primary hyperoxaluria
  • Focus Registrational; Therapeutic Use
  • Acronyms ILLUMINATE-B
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2018 New trial record
    • 25 Oct 2018 According to an Alnylam Pharmaceuticals media release, the Company also announced that it has aligned with the Food and Drug Administration (FDA) on a trial design for ILLUMINATE-B.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top